Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 9.05% and Operating profit at 7.40% over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
3
With ROE of 4.90%, it has a expensive valuation with a 1.70 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,954 Million (Small Cap)
35.00
NA
0.73%
0.17
4.90%
1.70
Revenue and Profits:
Net Sales:
339 Million
(Quarterly Results - Jun 2025)
Net Profit:
23 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.44%
0%
3.44%
6 Months
6.51%
0%
6.51%
1 Year
4.1%
0%
4.1%
2 Years
2.58%
0%
2.58%
3 Years
4.03%
0%
4.03%
4 Years
-17.81%
0%
-17.81%
5 Years
-15.99%
0%
-15.99%
Qingdao Vland Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.05%
EBIT Growth (5y)
7.40%
EBIT to Interest (avg)
20.12
Debt to EBITDA (avg)
0.74
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
0.51
Tax Ratio
25.12%
Dividend Payout Ratio
40.39%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.16%
ROE (avg)
7.19%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
1.70
EV to EBIT
29.57
EV to EBITDA
14.90
EV to Capital Employed
1.60
EV to Sales
2.41
PEG Ratio
NA
Dividend Yield
0.73%
ROCE (Latest)
5.40%
ROE (Latest)
4.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
338.60
318.90
6.18%
Operating Profit (PBDIT) excl Other Income
52.00
61.10
-14.89%
Interest
7.40
5.30
39.62%
Exceptional Items
4.20
7.90
-46.84%
Consolidate Net Profit
23.20
25.10
-7.57%
Operating Profit Margin (Excl OI)
71.70%
98.90%
-2.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 6.18% vs 3.10% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -7.57% vs 3.29% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,307.50
1,189.00
9.97%
Operating Profit (PBDIT) excl Other Income
225.60
178.60
26.32%
Interest
22.80
16.30
39.88%
Exceptional Items
6.60
4.90
34.69%
Consolidate Net Profit
92.20
102.90
-10.40%
Operating Profit Margin (Excl OI)
86.70%
87.70%
-0.10%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.97% vs 3.04% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -10.40% vs 20.49% in Dec 2023
About Qingdao Vland Biotech Co., Ltd. 
Qingdao Vland Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






